UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 91

Sortiert nach

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma

Biochemical pharmacology, 2011-04, Vol.81 (7), p.881-890

2011

Volltextzugriff (PDF)

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

The oncologist (Dayton, Ohio), 2019-11, Vol.24 (11), p.e1236-e1250

2019

Volltextzugriff (PDF)

Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2258-2263

2008

Volltextzugriff (PDF)

Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma

Viruses, 2021-07, Vol.13 (7), p.1406

2021

Volltextzugriff (PDF)

Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2

PloS one, 2014-06, Vol.9 (6), p.e95184

2014

Volltextzugriff (PDF)

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

Haematologica (Roma), 2012-06, Vol.97 (6), p.937-942

2012

Volltextzugriff (PDF)

Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study

Oncology, 2018-04, Vol.94 (5), p.274-280

2018

Volltextzugriff (PDF)

Limited-stage DLBCL: it's patient selection

Blood, 2018-01, Vol.131 (2), p.155-156

Persky, Daniel O.

2018

Volltextzugriff (PDF)

Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies

British journal of haematology, 2021-04, Vol.193 (1), p.15-25

2021

Volltextzugriff (PDF)

Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma

Haematologica (Roma), 2010-04, Vol.95 (4), p.597-603

2010

Volltextzugriff (PDF)

Cost-Effectiveness and Economic Burden Analyses on all First-Line Treatments of Chronic Lymphocytic Leukemia

Value in health, 2022-10, Vol.25 (10), p.1685-1695

2022

Volltextzugriff (PDF)

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Blood, 2015-01, Vol.125 (2), p.236-241

2015

Volltextzugriff (PDF)

Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI

Molecular imaging, 2016, Vol.15, p.153601211664543

2016

Volltextzugriff (PDF)

Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017)

Annals of hematology, 2021-10, Vol.100 (10), p.2501-2512

2021

Volltextzugriff (PDF)

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001

Journal of clinical oncology, 2020-09, Vol.38 (26), p.3003-3011

2020

Volltextzugriff (PDF)

Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves

Clinical lymphoma, myeloma and leukemia, 2021-11, Vol.21 (11), p.e820-e831

2021

Volltextzugriff (PDF)

Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience

Supportive care in cancer, 2021-08, Vol.29 (8), p.4867-4874

2021

Volltextzugriff (PDF)

Treatment of Early (Limited)-Stage DLBCL

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S34-S36

2020

Volltextzugriff (PDF)

Reply to E. Hawkes et al

Journal of clinical oncology, 2020-12, Vol.38 (35), p.4222-4223

2020

Volltextzugriff (PDF)

Phase 2 Trial of Combined Cisplatin, Etoposide, Gemcitabine, and Methylprednisolone (PEGS) in Peripheral T-Cell Non-Hodgkin Lymphoma: Southwest Oncology Group Study S0350

Cancer, 2013-01, Vol.119 (2), p.371-379

2013

Volltextzugriff (PDF)

A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806

American journal of hematology, 2018-04, Vol.93 (4), p.486-493

2018

Volltextzugriff (PDF)

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

JNCI : Journal of the National Cancer Institute, 2017-04, Vol.109 (4), p.djw249

2017

Volltextzugriff (PDF)

Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

Clinical cancer research, 2012-04, Vol.18 (8), p.2210-2219

2012

Volltextzugriff (PDF)

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

Leukemia & lymphoma, 2016-10, Vol.57 (10), p.2359-2369

2016

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(83)

Publikationsform

Sprache

Englisch
(89)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Life Sciences & Biomedicine
(41)
Humans
(35)
Oncology
(25)
Hematology
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Male
(19)
Female
(18)
Middle Aged
(18)
Aged
(15)
Adult
(14)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(10)
Rituximab
(10)
Aged, 80 And Over
(9)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Chemotherapy
(8)
Hematologic And Hematopoietic Diseases
(8)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(8)
Lymphoma
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(30)
Journal Of Clinical Oncology
(12)
Clinical Lymphoma, Myeloma And Leukemia
(4)
Haematologica
(3)
Oncology
(3)
American Journal Of Hematology
(2)
Biochemical Pharmacology
(2)
Cancer
(2)
Cancer Research
(2)
Leukemia & Lymphoma
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014

Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma

Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study

Limited-stage DLBCL: it's patient selection

Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies

Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma

Cost-Effectiveness and Economic Burden Analyses on all First-Line Treatments of Chronic Lymphocytic Leukemia

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI

Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017)

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001

Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves

Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission

Treatment of Early (Limited)-Stage DLBCL

Reply to E. Hawkes et al

Phase 2 Trial of Combined Cisplatin, Etoposide, Gemcitabine, and Methylprednisolone (PEGS) in Peripheral T-Cell Non-Hodgkin Lymphoma: Southwest Oncology Group Study S0350

A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

Suchergebnisse filtern